‘Columvi,' the first bispecific antibody treatment option for lymphoma, may be prescribed at general hospitals in Korea.

According to industry sources on the 9th, Roche Korea's CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) passed Samsung Medical Center’s drug committee review.

However, Columvi is currently a non-reimbursed drug. Its reimbursement application was reviewed by the Cancer Disease Deliberation Committee in July but was unable to set reimbursement standards at the time. Whether the company will quickly reorganize and reapply for coverage is gaining interest.

Columvi was approved in Korea last December for the treat